<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="114785">Erlotinib</z:chebi> is an oral, small-molecule targeting therapy which inhibits epidermal growth factor tyrosine kinase receptors </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="114785">Erlotinib</z:chebi> has been administered for the treatment of advanced <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> and <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: In the present report, unusual hematologic complications were detected after <z:chebi fb="0" ids="114785">erlotinib</z:chebi> was administered as second-line monotherapy in pretreated patients with advanced <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Four patients pre-treated with <z:chebi fb="2" ids="27899">cisplatin</z:chebi> or its analog-based combinations, were evaluated </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="114785">Erlotinib</z:chebi> was given at a dose of 150 mg daily </plain></SENT>
<SENT sid="5" pm="."><plain>In cases of intolerable adverse reactions, the dose was either reduced to 100 mg daily or treatment was interrupted for a maximum of two weeks </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Serious hematologic toxicity (or complications) developed in these 4 patients after 4-8.5 months of treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Two patients developed <z:hpo ids='HP_0001909'>leukemias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:mp ids='MP_0005481'>CML</z:mp>) and two, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Whether or not these hematologic complications were related to <z:chebi fb="0" ids="114785">erlotinib</z:chebi> treatment is comprehensively discussed </plain></SENT>
</text></document>